68 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
26 Mar 24
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update
7:12am
of 2025.
Research and development expenses were $37.2 million for the year ended December 31, 2023, compared to $30.3 million for 2022. The increase … data)
For the Year Ended December 31,
Consolidated Statements of Operations Data:
Operating Expenses:
Research and development
General and administrative
8-K
CGTX
Cognition Therapeutics Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:07pm
and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering to fund research, clinical development
424B5
CGTX
Cognition Therapeutics Inc
13 Mar 24
Prospectus supplement for primary offering
4:04pm
intend to use the net proceeds from this offering to fund research, clinical development, process development and manufacturing of our product candidates … and commissions and estimated offering expenses payable by us.
We currently intend to use the net proceeds from this offering to fund research
424B5
7abel1v5
11 Mar 24
Prospectus supplement for primary offering
4:06pm
8-K
EX-99.1
b192 sbpvudtfpzx
2 Nov 23
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:41am
8-K
EX-99.1
f09auj9axvd693f
8 Aug 23
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.1
94m0gc 3lhbrd
4 May 23
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
4:06pm
S-3
jkva 8vsjoqr34
23 Dec 22
Shelf registration
4:16pm
8-K
EX-99.1
po1 fee9n
14 Nov 22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
8:00am
424B4
hpghjqo5fz9yug7xolao
14 Nov 22
Prospectus supplement with pricing info
6:02am
DRS
ezhaq7fgchhdj
20 Oct 22
Draft registration statement
12:00am